These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 28668076)

  • 21. Highly activated and expanded natural killer cells for multiple myeloma immunotherapy.
    Garg TK; Szmania SM; Khan JA; Hoering A; Malbrough PA; Moreno-Bost A; Greenway AD; Lingo JD; Li X; Yaccoby S; Suva LJ; Storrie B; Tricot G; Campana D; Shaughnessy JD; Nair BP; Bellamy WT; Epstein J; Barlogie B; van Rhee F
    Haematologica; 2012 Sep; 97(9):1348-56. PubMed ID: 22419581
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor.
    Sutlu T; Stellan B; Gilljam M; Quezada HC; Nahi H; Gahrton G; Alici E
    Cytotherapy; 2010 Dec; 12(8):1044-55. PubMed ID: 20795758
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ex vivo expansion of natural killer cells from human peripheral blood mononuclear cells co-stimulated with anti-CD3 and anti-CD52 monoclonal antibodies.
    Masuyama J; Murakami T; Iwamoto S; Fujita S
    Cytotherapy; 2016 Jan; 18(1):80-90. PubMed ID: 26549384
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ex vivo-expanded natural killer cells kill cancer cells more effectively than ex vivo-expanded γδ T cells or αβ T cells.
    Deng X; Terunuma H; Terunuma A; Takane T; Nieda M
    Int Immunopharmacol; 2014 Oct; 22(2):486-91. PubMed ID: 25131561
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of ADAM10 and ADAM17 Inhibitors on Natural Killer Cell Expansion and Antibody-dependent Cellular Cytotoxicity Against Breast Cancer Cells
    Pham DH; Kim JS; Kim SK; Shin DJ; Uong NT; Hyun H; Yoon MS; Kang SJ; Ryu YJ; Cho JS; Yoon JH; Lee JS; Cho D; Lee SH; Park MH
    Anticancer Res; 2017 Oct; 37(10):5507-5513. PubMed ID: 28982863
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibiting TGF-beta signaling preserves the function of highly activated, in vitro expanded natural killer cells in AML and colon cancer models.
    Otegbeye F; Ojo E; Moreton S; Mackowski N; Lee DA; de Lima M; Wald DN
    PLoS One; 2018; 13(1):e0191358. PubMed ID: 29342200
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Natural killer cell-based adoptive immunotherapy eradicates and drives differentiation of chemoresistant bladder cancer stem-like cells.
    Ferreira-Teixeira M; Paiva-Oliveira D; Parada B; Alves V; Sousa V; Chijioke O; Münz C; Reis F; Rodrigues-Santos P; Gomes C
    BMC Med; 2016 Oct; 14(1):163. PubMed ID: 27769244
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expanded CD56
    Poznanski SM; Nham T; Chew MV; Lee AJ; Hammill JA; Fan IY; Butcher M; Bramson JL; Lee DA; Hirte HW; Ashkar AA
    Cancer Immunol Res; 2018 Oct; 6(10):1174-1185. PubMed ID: 30018043
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High log-scale expansion of functional human natural killer cells from umbilical cord blood CD34-positive cells for adoptive cancer immunotherapy.
    Spanholtz J; Tordoir M; Eissens D; Preijers F; van der Meer A; Joosten I; Schaap N; de Witte TM; Dolstra H
    PLoS One; 2010 Feb; 5(2):e9221. PubMed ID: 20169160
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity.
    Shah N; Martin-Antonio B; Yang H; Ku S; Lee DA; Cooper LJ; Decker WK; Li S; Robinson SN; Sekine T; Parmar S; Gribben J; Wang M; Rezvani K; Yvon E; Najjar A; Burks J; Kaur I; Champlin RE; Bollard CM; Shpall EJ
    PLoS One; 2013; 8(10):e76781. PubMed ID: 24204673
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor.
    Schönfeld K; Sahm C; Zhang C; Naundorf S; Brendel C; Odendahl M; Nowakowska P; Bönig H; Köhl U; Kloess S; Köhler S; Holtgreve-Grez H; Jauch A; Schmidt M; Schubert R; Kühlcke K; Seifried E; Klingemann HG; Rieger MA; Tonn T; Grez M; Wels WS
    Mol Ther; 2015 Feb; 23(2):330-8. PubMed ID: 25373520
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Umbilical cord mesenchymal stem cells increase expansion of cord blood natural killer cells.
    Boissel L; Tuncer HH; Betancur M; Wolfberg A; Klingemann H
    Biol Blood Marrow Transplant; 2008 Sep; 14(9):1031-1038. PubMed ID: 18721766
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy.
    Liu Y; Wu HW; Sheard MA; Sposto R; Somanchi SS; Cooper LJ; Lee DA; Seeger RC
    Clin Cancer Res; 2013 Apr; 19(8):2132-43. PubMed ID: 23378384
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ex vivo expansion of highly cytotoxic human NK cells by cocultivation with irradiated tumor cells for adoptive immunotherapy.
    Lim SA; Kim TJ; Lee JE; Sonn CH; Kim K; Kim J; Choi JG; Choi IK; Yun CO; Kim JH; Yee C; Kumar V; Lee KM
    Cancer Res; 2013 Apr; 73(8):2598-607. PubMed ID: 23580577
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
    Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
    Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preclinical evaluation and first-in-dog clinical trials of PBMC-expanded natural killer cells for adoptive immunotherapy in dogs with cancer.
    Razmara AM; Farley LE; Harris RM; Judge SJ; Lammers M; Iranpur KR; Johnson EG; Dunai C; Murphy WJ; Brown CT; Rebhun RB; Kent MS; Canter RJ
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38631708
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Radiotherapy enhances natural killer cell cytotoxicity and localization in pre-clinical canine sarcomas and first-in-dog clinical trial.
    Canter RJ; Grossenbacher SK; Foltz JA; Sturgill IR; Park JS; Luna JI; Kent MS; Culp WTN; Chen M; Modiano JF; Monjazeb AM; Lee DA; Murphy WJ
    J Immunother Cancer; 2017 Dec; 5(1):98. PubMed ID: 29254507
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I Trial of Expanded, Activated Autologous NK-cell Infusions with Trastuzumab in Patients with HER2-positive Cancers.
    Lee SC; Shimasaki N; Lim JSJ; Wong A; Yadav K; Yong WP; Tan LK; Koh LP; Poon MLM; Tan SH; Ow SGW; Bharwani L; Yap YS; Foo MZQ; Coustan-Smith E; Sundar R; Tan HL; Chong WQ; Kumarakulasinghe NB; Lieow JLM; Koe PJX; Goh BC; Campana D
    Clin Cancer Res; 2020 Sep; 26(17):4494-4502. PubMed ID: 32522887
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Good manufacturing practice-compliant cell sorting and large-scale expansion of single KIR-positive alloreactive human natural killer cells for multiple infusions to leukemia patients.
    Siegler U; Meyer-Monard S; Jörger S; Stern M; Tichelli A; Gratwohl A; Wodnar-Filipowicz A; Kalberer CP
    Cytotherapy; 2010 Oct; 12(6):750-63. PubMed ID: 20491532
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expansion of cytotoxic natural killer cells in multiple myeloma patients using K562 cells expressing OX40 ligand and membrane-bound IL-18 and IL-21.
    Thangaraj JL; Phan MT; Kweon S; Kim J; Lee JM; Hwang I; Park J; Doh J; Lee SH; Vo MC; Chu TH; Song GY; Ahn SY; Jung SH; Kim HJ; Cho D; Lee JJ
    Cancer Immunol Immunother; 2022 Mar; 71(3):613-625. PubMed ID: 34282497
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.